| Literature DB >> 35991270 |
Hongwei Ren1, Xiaobo Zhang2, Yu Tang3, Tao Yan4, Yuan Liu5.
Abstract
Objectives: To investigate the correlations of initial lab and imaging findings in COVID-19 patients of different clinical types.Entities:
Keywords: Artificial intelligence; Clinical characteristics; Computed tomography; Coronavirus Disease 2019; Imaging features
Year: 2022 PMID: 35991270 PMCID: PMC9378371 DOI: 10.12669/pjms.38.6.5091
Source DB: PubMed Journal: Pak J Med Sci ISSN: 1681-715X Impact factor: 2.340
Fig.1ACOVID-19 (common type), male, 27 years old, with the visibility of ground-glass nodular (GGN) shadow at the subpleural regions of the upper lobes of both lungs, with h alo sign-like change around.
Fig.1B: COVID-19 (common type), male, 59 years old, with the visibility of multiple ground-glass opacity (GGO) at the bilateral subpleural regions and fuzzy boundary, as well as thickened vascular shadows in some lesions.
Fig.1C: COVID-19 (common type), female, 44 years old, with the presence of patchy consolidation shadow in the lower lobes of both lungs, air bronchogram sign in the lesions and halo sign-like change around the lesions at the lower lobe of the right lung.
Fig.1D: COVID-19 (severe type), female, 74 years old, with the visibility of multiple ground-glass opacity (GGO) in both lungs with partial consolidation and interlobular septal t hickening, showing a grid-like change.
Fig.1ECOVID-19 (critical type), male, 79 years old, with the visibility of band-like high-density shadows at the subpleural regions of the upper lobes of both lungs, parallel to the pleura, and with the presence of interlobular septal thickening in the lesions, showing a crazy-paving sign-like change.
Fig.1F: COVID-19 (critical type), female, 50 years old, with the visibility of multiple GGO and consolidation in both lungs, as well as air bronchogram sign in the lesions.
Comparisons of chest CT images between the mild group and the severe group (n).
| Variables | Mild group (common type) (n=34) | Severe group (n=17) | Test value | P-value |
|---|---|---|---|---|
| Distribution of lesions, n | 0.542 | |||
| Left lung only | 0 | 0 | ||
| Right lung only | 3 | 0 | ||
| Botd lungs | 31 | 17 | ||
| Density of lesions | 0.831 | |||
| GGO | 23 | 12 | 0.04 | |
| Consolidation | 8 | 13 | 13.114 | |
| Mixed GGO | 17 | 14 | 4.977 | |
| Pleural effusion | 2 | 5 | - | 0.034 |
| Percentage of pneumonia lesions in tde volume of tde whole lung (%) | 2.42(0.04~4.19) | 11.54 (2.26~18.64) | 10.662 | 0.001 |
: COVID-19, Corona Virus Disease 2019; GGO, ground-glass opacity; -, the Fisher exact probability method was used, without statistics.
Comparisons in laboratory indexes in COVID-19 patients between the mild group and the severe group.
| Grouping | Mild group | Severe group | Test value | P-value |
|---|---|---|---|---|
| Blood routine test and inflammatory factors | ||||
| WBC (×109/L) | 4.95 (4.19~6.42) | 6.76 (3.65~9.46) | -1.74 | 0.082 |
| < 4 | 10/41 (24.4%) | 5/17 (29.4%) | - | 0.747 |
| 4-10 | 29/41 (70.7%) | 10/17 (58.8%) | 0.774 | 0.379 |
| > 10 | 2/41 (4.8%) | 2/17 (11.8%) | - | 0.055 |
| ANC (×109/L) | 2.76 (2.14~4.11) | 5.52 (2.78~8.31) | -2.673 | 0.008 |
| > 7 | 2/41 (4.8%) | 4/17 (23.5%) | - | 0.002 |
| ALC (×109/L) | 1.59 ± 0.68 | 0.79 ± 0.41 | 4.641 | 0.000 |
| < 0.8 | 5/41 (12.2%) | 9/17 (52.9%) | - | 0.002 |
| CRP (mg/l) | 2.35 (1.18~7.17) | 8.26 (3.33~8.26) | -2.787 | 0.005 |
| > 8.2 | 10/41 (24.4%) | 8/17 (47.1%) | 2.889 | 0.085 |
| IL-6 (pg/ml) | 5.18 (3.69~7.19) | 8.95 (4.43~35.27) | -1.995 | 0.046 |
| > 7 | 13/41 (31.7%) | 10/17 (58.8%) | 3.693 | 0.055 |
| PCT (ng/ml) | 0.04 (0.031~0.052) | 0.057 (0.03~0.19) | -1.939 | 0.053 |
| > 0.5 | 20/41 (48.8%) | 10/17 (58.8%) | 0.485 | 0.486 |
| D-D (mg/l) | 0.28 (0.22~0.46) | 2.66 (0.66~5.03) | -5.099 | 0.000 |
| > 0.55 | 7/41 (17.1%) | 12/17 (70.6%) | 15.624 | 0.000 |
| Biochemical indexes of liver | ||||
| ALT (u/l) | 21.0 (14.0~36.0) | 30.0 (14.75~93.75) | -0.842 | 0.400 |
| > 40 | 8/41 (19.5%) | 8/17 (47.1%) | - | 0.052 |
| AST (u/l) | 23.0 (18.5~28.5) | 28.0 (19.0~47.75) | -1.311 | 0.190 |
| > 40 | 7/41 (17.1%) | 5/17 (29.4%) | - | 0.307 |
| Alb (g/l) | 38.49 ± 4.49 | 32.28 ± 6.29 | 1.789 | 0.186 |
| TBil (μmol/l) | 11.0 (7.70~14.75) | 11.8 (8.23~14.5) | -0.226 | 0.821 |
| ALP (u/l) | 66.0 (58.5~85.0) | 64.5 (46.5~79.25) | -1.118 | 0.264 |
| GGT (u/l) | 23.0 (13.0~42.5) | 51.0 (19.25~63.0) | -2.534 | 0.011 |
| Cardiac function indexes | ||||
| LDH (u/l) | 199.5 ± 150.09 | 292.94 ± 113.34 | -3.378 | 0.003 |
| > 245 | 5/41 (12.2%) | 10/17 (58.8%) | - | 0.001 |
| hcTnT (ng/ml) | 0.004 (0.003~0.006) | 0.0065(0.003~0.016) | -1.571 | 0.116 |
| > 0.1 | 2/41 (4.8%) | 5/17 (29.4%) | - | 0.019 |
| CK-MB (ng/ml) | 0.65 (0.47~1.01) | 1.12 (0.60~2.15) | -2.363 | 0.018 |
| BNP (pg/ml) | 33.15 (12.49~137). | 276.35 (59.30~743.88) | -3.900 | 0.000 |
| > 125 | 10/41 (24.4%) | 10/17 (58.8%) | 6.307 | 0.012 |
: COVID-19, Corona Virus Disease 2019; WBC, white blood cell count;
ANC, absolute neutrophil count; ALC, absolute lymphocyte count; CRP, C reactive protein;
IL-6, interleukin-6; PCT, procalcitonin; D-D, D-Dimer; ALT, alanine aminotransferase;
AST, aspartate aminotransferase; Alb, albumin; TBil, total bilirubin; ALP, alkaline phosphatase;
GGT, gamma-glutamyltransferase; LDH, lactic dehydrogenase;
hs-cTnT, high-sensitivity cardiac troponin T; CK-MB, creatine Kinase Isoenzyme-MB;
BNP, brain natriuretic peptide; and -, the Fisher exact probability method was used, without statistic.